低剂量纳米白蛋白结合型紫杉醇治疗HER2阴性转移性乳腺癌的安全性和有效性
Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
作者信息
Takashima Tsutomu, Kawajiri Hidemi, Nishimori Takeo, Tei Seika, Nishimura Shigehiko, Yamagata Shigehito, Tokunaga Shinya, Mizuyama Yoko, Sunami Takeshi, Tezuka Kenji, Ikeda Katsumi, Ogawa Yoshinari, Kashiwagi Shinichiro, Noda Satoru, Onoda Naoyoshi, Ishikawa Tetsuro, Kudoh Shinzoh, Takada Minoru, Hirakawa Kosei, Ohira Masaichi
机构信息
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan
Department of Breast Surgery, Ishikiri Seiki Hospital, Osaka, Japan.
出版信息
Anticancer Res. 2018 Jan;38(1):379-383. doi: 10.21873/anticanres.12233.
BACKGROUND/AIM: Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel formulation. Although nab-PTX has shown superior efficacy compared to conventional paclitaxel (PTX) in metastatic breast cancer (MBC), chemotherapy-induced peripheral neuropathy (CIPN) was more frequently observed in nab-PTX. In this study, we aimed to estimate the feasibility of the nab-PTX 175 mg/m/3weeks regimen.
PATIENTS AND METHODS
Patients having metastatic or inoperable HER2-negative breast cancer received 175 mg/m of nab-PTX every three weeks. The primary endpoint was safety and the secondary endpoints were response and survival.
RESULTS
Seventeen patients were enrolled with a median age of 64 years. Ten patients had estrogen receptor positive disease and seven had triple-negative disease. CIPN was observed in seven patients (41%) however, grade 3 CIPN was only seen in one patient (6%). Objective response rate was 41% and progression-free survival was 23 weeks.
CONCLUSION
Nab-PTX 175 mg/m/3wks regimen has a good safety profile and less frequent CIPN. This regimen can contribute to the strategy of MBC treatment.
背景/目的：纳米白蛋白结合型紫杉醇（nab-PTX）是一种白蛋白结合型紫杉醇制剂。尽管在转移性乳腺癌（MBC）中，nab-PTX已显示出比传统紫杉醇（PTX）更优的疗效，但nab-PTX治疗导致的化疗引起的周围神经病变（CIPN）更为常见。在本研究中，我们旨在评估nab-PTX 175mg/m²/3周方案的可行性。
患者与方法
患有转移性或不可手术切除的HER2阴性乳腺癌的患者每三周接受175mg/m²的nab-PTX治疗。主要终点为安全性，次要终点为缓解率和生存率。
结果
共纳入17例患者，中位年龄64岁。10例患者为雌激素受体阳性疾病，7例为三阴性疾病。7例患者（41%）出现CIPN，然而，仅1例患者（6%）出现3级CIPN。客观缓解率为41%，无进展生存期为23周。
结论
nab-PTX 175mg/m²/3周方案具有良好的安全性，且CIPN发生率较低。该方案可为MBC的治疗策略做出贡献。
Zotero 插件